Home Guides Getting Tirzepatide Covered
Getting Tirzepatide Covered: Prior Authorisation and the Appeal That Works
A large share of first-pass prior authorisation requests are denied, and most denials are reversible. The four documentation gaps that trigger most denials are missing BMI history, missing c…
A large share of first-pass prior authorisation requests are denied, and most denials are reversible. The four documentation gaps that trigger most denials are missing BMI history, missing comorbidity coding, no documented lifestyle intervention, and no record of prior therapy.
On this page
What insurers typically require
BMI ≥30, or ≥27 with at least one weight-related comorbidity — commonly hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease or osteoarthritis. Many plans also require documented participation in a lifestyle intervention for a set period, and some require a trial of a preferred alternative first.
Bring these to the visit
Weight and BMI documented at multiple points over at least six months. ICD-10 codes for every comorbidity you actually have. A record of previous weight-management attempts with dates. Any sleep study results. Prior GLP-1 trials with dates, doses and outcomes if you have them.
The obstructive sleep apnea route
Zepbound holds a specific FDA indication for moderate-to-severe OSA in adults with obesity, approved December 2024 on the strength of SURMOUNT-OSA. Plans that categorically exclude weight-loss drugs frequently do cover treatment for a diagnosed sleep disorder. If OSA is plausible for you, pursue the diagnosis first — it is the highest-yield move in this entire process.
Appealing a denial
Request the specific denial reason and the clinical criteria in writing. Have your prescriber request a peer-to-peer review — a physician-to-physician conversation reverses a meaningful share of denials that paperwork alone does not. If internal appeals fail, external review by an independent entity is available in every state.
Run a compounded or LillyDirect self-pay path in parallel rather than waiting. Appeals take weeks, and stopping treatment while you wait costs you progress.
Common questions
Does insurance cover tirzepatide?
It depends on your plan and your diagnosis. Many commercial plans exclude weight-management drugs entirely. Zepbound carries a specific FDA indication for moderate-to-severe obstructive sleep apnea with obesity, and plans that exclude weight loss often cover a diagnosed sleep disorder. With type 2 diabetes, Mounjaro is on-label.
What are the most common tirzepatide side effects?
Nausea (roughly 24–33%), diarrhea (19–23%), constipation (16–17%) and vomiting (8–12%). They cluster in the days after each dose increase and usually settle within one to two weeks at each new dose. Constipation is the one that most often persists.
Do I need a prescription for tirzepatide?
Yes, always — for brand and compounded alike. Any seller shipping tirzepatide without a prescription from a licensed prescriber is operating illegally, and the product should not be considered pharmaceutical grade.
Can I switch from semaglutide to tirzepatide without starting over?
You restart at 2.5 mg tirzepatide regardless of your semaglutide dose, because there is no equivalence between the molecules. Most switchers find re-titration far easier than a first start — roughly 13% report GI symptoms — because GLP-1 receptor adaptation carries over. Take the first tirzepatide dose about seven days after your last semaglutide injection.
People also ask about tirzepatide insurance appeal
What is tirzepatide insurance appeal?
Tirzepatide insurance appeal is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide insurance appeal apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide insurance appeal cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide insurance appeal FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.